title: Induced apoptosis in human prostate cancer cell line LNCaP by Ukrain.
abstract: Exposure of LNCaP prostate cancer cells to Ukrain (NSC-631570), a novel semisynthetic drug from Chelidonium majus L., results in cell growth inhibition which is concomitant with apoptosis. After 24 h treatment with 3.5 microM of Ukrain as many as 73% cells were found in the G2/M phase. However, at higher drug concentrations (7 microM and 17.5 microM) the changes in cell phase distribution were less dramatic but cell accumulation in the G2/M phase was still evident. The rate of apoptotic cells rose steadily with increased drug concentration in a dose-dependent manner and reached 20% at a dosage of 17.5 microM. To investigate whether the cell cycle control mechanisms are affected in response to Ukrain, we analyzed the expression levels of some cyclins, cyclin-dependent kinases (CDK) and apoptosis-related proteins in drug treated cancer cells. Western blot experiments revealed alterations in levels of CDK1 and CDK2, after treatment. Up-regulation of the CDK inhibitor p27 was observed, which may lead to G2/M cell accumulation, but no substantial changes in expression of Bcl-2 and Bax proteins were found.
authors.affiliation: Department of Dermatology, University of Rochester School of Medicine and Dentistry, Rochester, USA.
authors.forename: I N
authors.initials: IN
authors.lastname: Roublevskaia
authors.forename: A R
authors.initials: AR
authors.lastname: Haake
authors.forename: J W
authors.initials: JW
authors.lastname: Ludlow
authors.forename: B V
authors.initials: BV
authors.lastname: Polevoda
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D001600:Berberine Alkaloids; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000096:biosynthesis; D050760:Cyclin-Dependent Kinase Inhibitor p27; D018844:Cyclin-Dependent Kinases / Q000096:biosynthesis; D004273:DNA, Neoplasm / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D010617:Phenanthridines; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D014407:Tumor Cells, Cultured; D025521:Tumor Suppressor Proteins; D051028:bcl-2-Associated X Protein
chemical_list: D000470:Alkaloids; D000972:Antineoplastic Agents, Phytogenic; C494826:BAX protein, human; D001600:Berberine Alkaloids; D018797:Cell Cycle Proteins; D004273:DNA, Neoplasm; D010617:Phenanthridines; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D025521:Tumor Suppressor Proteins; D051028:bcl-2-Associated X Protein; D050760:Cyclin-Dependent Kinase Inhibitor p27; C060921:ukrain; D018844:Cyclin-Dependent Kinases